Loading...
XKRX
358570
, Last price  
KRW
Name

GI Innovation Inc

Chart & performance

D1W1MN
XKRX:358570 chart
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
7.30%
Rev. 5Y
-11.93%
Div Yld LY
—
Div Yld TTM
—
Revenues
5.84b
+23,943.85%
3,513,610,49011,016,789,0005,600,000,0003,500,000,0005,318,849,00024,281,0005,838,087,000
Net income
-35.13b
L-40.23%
-49,196,431,530-75,933,174,000-150,741,996,000-79,833,059,000-55,495,299,000-58,784,457,000-35,134,798,000
CFO
-32.30b
L-25.62%
-16,424,153,000-15,182,158,000-26,577,491,000-62,550,424,556-41,174,491,000-43,426,716,000-32,302,679,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

GI Innovation, Inc. specializes in the research and creation of biopharmaceutical products. Its current developmental portfolio features drug candidates G-101, G-102, G-301, and G-108. Founded by Jang Myoung-ho on July 19, 2017, the company's main operations are situated in Seoul, South Korea.
URL
https://www.gi-innovation.com/
IPO date
Mar 30, 2023
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT